Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.dsx.2020.07.011 http://scihub22266oqcxt.onion/10.1016/j.dsx.2020.07.011 32683320!7352102!32683320     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Metab+Syndr 2020 ; 14 (5): 1225-1229 Nephropedia Template TP {{tp|p=32683320|t=2020. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19) |pdf=|usr=}}{{32683320}} gab.com Text Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19) JO: Diabetes Metab Syndr http://www.kidney.de/pget.php?&tw=1&pmid=32683320 #FOAvip BACKGROUND AND AIMS: Morbidity and mortality from coronavirus disease 2019 (COVID-19) is higher among people with diabetes mellitus (DM), hypertension, and cardiovascular disease (CVD). Statins are used in the majority of people with DM and CVD. This mini-review discusses the current understanding of benefit-risk ratio of use of statins in COVID-19. METHODS: We searched PubMed database using specific keywords related to our aims till June 12, 2020. Full text of relevant articles published in English language were retrieved and reviewed. RESULTS: Statins, with their immunomodulatory, anti-inflammatory, anti-thrombotic, and anti-oxidant properties, have the potential to reduce severity of lung injury in, and mortality from, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infections. Statin-induced upregulation of angiotensin-converting enzyme-2 (ACE2) has the potential to reduce lung injury from excess angiotensin II. By disrupting lipid rafts, statins have the potential to reduce viral entry into cells. However, benefit-risk ratio of its complex interaction with MYD88 gene expression on outcomes in COVID-19, and the putative role of low serum LDL cholesterol in increasing severity of SARS-CoV2 infection need further clarification. CONCLUSIONS: People with COVID-19, who are already on statins for an underlying co-morbid condition, should continue on it unless there are specific contraindications. De-novo use of statins in people with COVID-19 with no underlying co-morbidity might be beneficial but awaits substantiation in clinical trials; till that time, de novo use of statins in COVID 19 should be limited to a clinical trial setting. Twit Text FOAVip Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19) ????Diabetes Metab Syndr http://www.kidney.de/pget.php?&tw=1&pmid=32683320 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32683320 #FOAvip English Wikipedia <ref>{{Cite pmid|32683320}}</ref> Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19) #MMPMID32683320 Subir R; Jagat J M; Kalyan K G Diabetes Metab Syndr 2020[Sep]; 14 (5): 1225-1229 PMID32683320show ga BACKGROUND AND AIMS: Morbidity and mortality from coronavirus disease 2019 (COVID-19) is higher among people with diabetes mellitus (DM), hypertension, and cardiovascular disease (CVD). Statins are used in the majority of people with DM and CVD. This mini-review discusses the current understanding of benefit-risk ratio of use of statins in COVID-19. METHODS: We searched PubMed database using specific keywords related to our aims till June 12, 2020. Full text of relevant articles published in English language were retrieved and reviewed. RESULTS: Statins, with their immunomodulatory, anti-inflammatory, anti-thrombotic, and anti-oxidant properties, have the potential to reduce severity of lung injury in, and mortality from, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infections. Statin-induced upregulation of angiotensin-converting enzyme-2 (ACE2) has the potential to reduce lung injury from excess angiotensin II. By disrupting lipid rafts, statins have the potential to reduce viral entry into cells. However, benefit-risk ratio of its complex interaction with MYD88 gene expression on outcomes in COVID-19, and the putative role of low serum LDL cholesterol in increasing severity of SARS-CoV2 infection need further clarification. CONCLUSIONS: People with COVID-19, who are already on statins for an underlying co-morbid condition, should continue on it unless there are specific contraindications. De-novo use of statins in people with COVID-19 with no underlying co-morbidity might be beneficial but awaits substantiation in clinical trials; till that time, de novo use of statins in COVID 19 should be limited to a clinical trial setting. |Betacoronavirus/*isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/drug therapy/*epidemiology/*prevention & control/transmission/virology[MESH] |Humans[MESH] |Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use[MESH] |Incidence[MESH] |India/epidemiology[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/*epidemiology/*prevention & control/transmission/virology[MESH] |Prognosis[MESH]Pros and cons for use of statins in people with coronavirus disease-19(epmc).pdf DeepDyve Pubget Overpricing